Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290740 | 0.89 | KCNH2 (0.36) | KCNH2PGRARKDM4EENPP3 | |
| SCHEMBL4720561 | 0.87 | KCNH2 (0.38) | KCNH2PGRARKDM4EENPP3 | |
| SCHEMBL4775279 | 0.85 | ENPP3 (0.41) | KCNH2ARKDM4EENPP3ALPL | |
| SCHEMBL14291053 | 0.78 | ENPP3 (0.42) | KCNH2ARENPP3ALPLXIAP | |
| SCHEMBL14304003 | 0.74 | KCNH2 (0.49) | KCNH2PGRRORC | |
| SCHEMBL4716327 | 0.73 | ENPP3 (0.43) | KCNH2ARENPP3ALPLXIAP | |
| SCHEMBL508732 | 0.71 | KCNH2 (0.46) | KCNH2AREPAS1CYP3A4 | |
| SCHEMBL14303592 | 0.68 | KCNH2 (0.44) | KCNH2ARENPP3ALPLXIAP | |
| SCHEMBL509441 | 0.68 | KCNH2 (0.39) | KCNH2CYP3A4 | |
| SCHEMBL509286 | 0.67 | EPAS1 (0.40) | ARENPP3ALPLXIAPEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | KCNH2 2921/4885PGR 768/4885AR 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.